[caption id="attachment_73544" align="aligncenter" width="500"] Pexels[/caption]
The diagnosis comes, and the inbox fills up. Therapy acronyms. Insurance forms. Well-meaning relatives forwarding articles. Somewhere in the noise, three letters keep appearing: ABA. Your pediatrician mentions it. Your insurance company asks about it. The waitlist conversations are all built around it.
What nobody quite explains, in the first dizzy weeks after a diagnosis, is what ABA actually is — what it does, what it doesn't do, and how to tell a quality program from a low-quality one.
Pexels[/caption]
The diagnosis comes, and the inbox fills up. Therapy acronyms. Insurance forms. Well-meaning relatives forwarding articles. Somewhere in the noise, three letters keep appearing: ABA. Your pediatrician mentions it. Your insurance company asks about it. The waitlist conversations are all built around it.
What nobody quite explains, in the first dizzy weeks after a diagnosis, is what ABA actually is — what it does, what it doesn't do, and how to tell a quality program from a low-quality one.
Applied Behavior Analysis (ABA) therapy is an evidence-based treatment for individuals with autism spectrum disorder and other developmental disorders. ABA therapy is a personalized treatment plan that focuses on improving behavior, social interaction, and more, simultaneously focusing on the person’s strengths and weaknesses. For this reason, it is crucial to plan the treatment effectively. While the treatment itself has been groundbreaking, it does come with a set of challenges. This article explores the challenges of ABA treatment planning with practical solutions.
Dr. Walsh[/caption]
Christopher Walsh, M.D., Ph.D.
Chief, Division of Genetics and Genomics
Bullard Professor of Pediatrics and Neurology at Harvard Medical School
and researcher who has used material donated to the brain bank
MedicalResearch.com: What is the background for this study?
Response: Many different types of genetic variants contribute to neurodevelopmental disorders such as autism. Copy number variants are large pieces of genetic material that are duplicated or deleted. We have known for many years that many copy number variants at certain genetic locations are linked to autism. Because these copy number variants may include lots of different genes, it has been difficult to understand how these copy number variants alter human brain function. Furthermore, although animal models are important, autism is in many ways defined by differences in uniquely human cognitive and social functioning. Better understanding of how these copy number variants change human brain function will shed light on universal mechanisms that regulate neurodevelopment. We studied a copy number variant called dup15q, that is associated with almost 40-fold higher rates of autism vs. the general population. We studied post-mortem human brain tissue from individuals with dup15q, individuals with autism not related to dup15q, and neurotypical controls, to better understand how the human brain is impacted by dup15q. We focused on frontal cortex, an important brain region in executive function and social perspective taking. We applied cutting edge techniques that allow us to assess individual cells in the brain. 
Dr. Pierce[/caption]
Karen Pierce, Ph.D.
Professor, Department of Neurosciences, UCSD
Co-Director, Autism Center of Excellence, UCSD
MedicalResearch.com: What is the background for this study?
Response: The mean age of ASD diagnosis and eventual treatment remains at ~52 months in the United States1 - years beyond the disorder’s prenatal origins2, and beyond the age when it can be reliably diagnosed in many cases3.
Currently the only way to determine if a child has autism spectrum disorder (ASD) is to receive a developmental evaluation from an experienced clinician (usually a licensed clinical psychologist). There are often long waiting lists, and only a small number of clinicians have the experience required to make early-age (i.e., between 12-36 months) diagnoses of ASD. Thus, there are many places in the country as well as world wide wherein children wait months or years to receive a formal diagnosis due to a lack of available expertise. Moreover, diagnostic evaluations are expensive and usually cost the parent and/or insurance approximately ~$2,000 or more per evaluation. Finally, clinical evaluations usually take between 2-3 hours to complete and result in fatigue for both the parent and toddler.
Eye-tracking, which generates biologically-relevant, objective, and quantifiable metrics of both visual and auditory preference profiles in babies and toddlers in just minutes, is a technology that can dramatically change how ASD is diagnosed.
